Key Highlights

  • Third-quarter Revenue reached EUR 1.3 billion, below EUR 1.5 billion a year earlier, a decline the company tied mainly to weaker expected Demand for its COVID-19 vaccine, as disclosed on November 3, 2026.
  • Partnership revenue of EUR 613 million tied to the bispecific antibody pumitamig, booked under the BMS arrangement, cushioned the top-line drop during the quarter.
  • Cash equivalents and security investments totaled EUR 16.2 billion at quarter-end, and the company had repurchased about 5 million shares since June.
  • The 2026 revenue outlook now runs from EUR 1.7 to 1.9 billion with the midpoint raised, while adjusted R&D guidance stays at EUR 2.0 to 2.3 billion.

Partnership Income Softens a Vaccine-Led Revenue Decline

BioNTech (NASDAQ:BNTX) discussed third-quarter 2026 results on a call held November 3, 2026. Sales came in at EUR 1.3 billion, compared with EUR 1.5 billion a year before, and management pinned the shortfall largely on a forecast drop in demand for its COVID-19 shot. Partnership accounting carried a heavier load, since EUR 613 million was booked under the arrangement with BMS covering joint development and commercialization of pumitamig, meaning much of the period's revenue did not come from direct product sales. Through nine months, revenue totaled EUR 1.5 billion compared with EUR 2 billion. Even so, the midpoint of the 2026 revenue forecast moved higher, now spanning EUR 1.7 to 1.9 billion.

Research Costs Climb as the Oncology Pipeline Widens

Adjusted Research and Development spending climbed to EUR 579 million from EUR 479 million, driven by work in immuno-oncology and antibody-drug conjugate programs. Under IFRS, R&D came to EUR 748 million, because another EUR 169 million consisted of Impairment charges on intangible assets that fall outside the company's strategic focus. Selling, general and administrative costs rose to EUR 179 million from EUR 149 million, reflecting pre-launch preparation, commercial buildout and an ERP system upgrade, partly offset by savings from narrowing the pipeline. Adjusted R&D reached EUR 1.6 billion over nine months and adjusted SG&A reached EUR 527 million, up from EUR 407 million. Guidance for adjusted R&D of EUR 2.0 to 2.3 billion and SG&A of EUR 700 to 800 million is unchanged. With EUR 16.2 billion in cash and securities, management believes it can pursue its goal of becoming a multi-product company by 2030.

Trial Readouts Are Mixed as Leadership Changes Hands

Clinical updates were a mixed bag. In a non-pivotal segment of a squamous lung cancer study, gotistobart delivered median overall survival of 18.5 months against 10 months for docetaxel, with a hazard ratio of 0.56, and a first interim look at the pivotal part is slated before year-end. AHEAD-MERIT did not hit its first primary goal, progression-free survival, yet it keeps moving toward overall survival. T-Pam achieved its progression-free survival target, though the company described the gain as modest and reported a higher rate of interstitial lung disease, while a colorectal study of autogene cevumeran was stopped. Uğur Şahin presented his final earnings call, and Guido Oelkers becomes CEO by February 1 at the latest. Six phase III studies began this year, and early response figures came from small patient groups that may not carry over to larger trials.

Where Things Stand

The BMS partnership is what cushioned the decline: EUR 613 million of quarterly revenue came from that arrangement while Vaccine demand weakened. BioNTech (NASDAQ:BNTX) still lifted the midpoint of its 2026 revenue outlook and holds EUR 16.2 billion in cash and securities, yet research and sales costs are climbing and several trial readouts were mixed. The interim gotistobart analysis before year-end, the CEO transition and any decision on a T-Pam filing are the next markers to watch.